Regeneron antibody earns nod for rare cholesterol disorder — but it ain't cheap
Regeneron has a new approved drug to add to its stable of monoclonal antibodies.
The FDA gave the thumbs-up to the biotech’s evinacumab, to be called Evkeeza, as a supplement to other LDL-lowering treatments for the rare genetic disorder homozygous familial hypercholesterolemia. Evkeeza has been indicated for patients older than 12 and is priced based on weight, but Regeneron expects it will cost an average of $450,000 per year.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
